Niagen Bioscience, Inc. (NAGE)vsVertex Pharmaceuticals Inc (VRTX)
NAGE
Niagen Bioscience, Inc.
$4.52
-0.44%
HEALTHCARE · Cap: $373.18M
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 9173% more annual revenue ($12.00B vs $129.42M). VRTX leads profitability with a 32.9% profit margin vs 13.4%. NAGE trades at a lower P/E of 23.3x. VRTX earns a higher WallStSmart Score of 66/100 (B-).
NAGE
Hold45
out of 100
Grade: D
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-275.7%
Fair Value
$1.36
Current Price
$4.52
$3.16 premium
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 28 in profit
16.2% revenue growth
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
Earnings declined 41.6%
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NAGE
The strongest argument for NAGE centers on Return on Equity, Revenue Growth. Revenue growth of 16.2% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : NAGE
The primary concerns for NAGE are Market Cap, EPS Growth.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
NAGE profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.
NAGE carries more volatility with a beta of 2.23 — expect wider price swings.
NAGE is growing revenue faster at 16.2% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 45/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Niagen Bioscience, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Niagen Bioscience, Inc. is a bioscience company engages in developing healthy aging products. The company is headquartered in Los Angeles, California.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?